← Eichor
Condition: Inflammatory Dry Eye Disease Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Inflammatory Dry Eye Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06828042A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Phase 1 · 19 location(s) · GlaxoSmithKline · NCT07371468An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NA · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06379646Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Diseas
Phase N/A · 1 location(s) · Hospital Universitario Araba · NCT07249060Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases
Phase N/A · 1 location(s) · Centre Hospitalier Régional d'Orléans · NCT06842316MTS109 in Patients With Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT07526350A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Phase 1 · 1 location(s) · Xencor, Inc. · NCT07284797Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Phase 1 · 2 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236801AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Stud
Phase 2 · 52 location(s) · Artiva Biotherapeutics, Inc. · NCT06991114Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Nanjing Bioheng Biotech Co., Ltd. · NCT06548607The Pattern of Dry Eye Disease After Cataract Surgery
Phase N/A · 1 location(s) · Lithuanian University of Health Sciences · NCT06298890Rare AutoImmune SElf-management Programme Development
Phase N/A · 1 location(s) · University of the West of England · NCT06642870Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06350110Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07361094Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT
Phase 1/Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07062523An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236762Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NI
Phase 1 · 52 location(s) · National Cancer Institute (NCI) · NCT03816345A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Therorna · NCT07413341Ocular Complications From Cancer Therapy - Patient Registry and Biobank
Phase N/A · 1 location(s) · University of Maryland, Baltimore · NCT06874283BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06794008
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.